What is Mallinckrodt Profitability Rank?
Mallinckrodt has the Profitability Rank of 4.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Mallinckrodt's Operating Margin % for the quarter that ended in Sep. 2023 was -0.82%. As of today, Mallinckrodt's Piotroski F-Score is 3.
Competitive Comparison of Mallinckrodt's Profitability Rank
For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mallinckrodt's Profitability Rank Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Mallinckrodt's Profitability Rank falls into.
Mallinckrodt Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Mallinckrodt has the Profitability Rank of 4.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Mallinckrodt's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Mallinckrodt has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Mallinckrodt (Mallinckrodt) Business Description
Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
| Alta Fundamental Advisers Llc |
10 percent owner |
1500 BROADWAY, SUITE 704, NEW YORK NY 10036 |
| Jason Daniel Goodson |
officer: EVP & Head of Corp Development |
106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885 |
| James R Sulat |
director |
|
| Paul Bisaro |
director |
|
| Sigurdur O Olafsson |
director, officer: President and CEO |
360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960 |
| Stephen Andrew Welch |
officer: EVP & Head of Spec Generics |
18440 BRIDGEMORE LANE, LOUISVILLE KY 40245 |
| Peter C Richardson |
officer: EVP & Chief Scientific Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Susan Michele Silbermann |
director |
C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
| Lisa French |
officer: EVP & Chief Commercial Officer |
301 CONTINENTAL LANE, PAOLI PA 19301 |
| Mark Anthony Tyndall |
officer: EVP & Chief Legal Offi & Secre |
1101 Q ST NW, WASHINGTON DC 20009 |
| Henriette Nielsen |
officer: EVP & Chief Transformation OFC |
202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024 |
| Karen Ling |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Anne Clem Whitaker |
director |
109 BRIERY BRANCH COURT, MORRISVILLE NC 27560 |
| Olifant Luxco S.a R.l. |
10 percent owner |
19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273 |
| Paul Rutherford Carter |
director |
SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your